Clinical Trials Genetic Analysis Genetics 
XTalks
JULY 29, 2024
Orphan drug development poses many challenges that are unique to rare diseases, including recruitment in small patient populations, variable progression with heterogenous clinical manifestations and limited understanding of disease progression and natural history. Read on to learn key lessons in rare disease drug development.
XTalks
DECEMBER 1, 2020
As the research and medical community learns more about population variances in disease outcomes, whether as a result of regional genetic profiles, socioeconomic factors, or environmental inputs, it’s become necessary to ensure that clinical research trials include broad swaths of global participants. billion in 2019.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
MARCH 13, 2023
Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision about whether to participate in a clinical trial, and what kind of treatment effects would be most meaningful to them?
XTalks
MARCH 7, 2024
Experts discuss the therapeutic landscape, treatment gaps, regulatory considerations and clinical trial strategies. Breast Cancer Multiomics: Unified Insights in Tumor Heterogeneity This on-demand webinar introduces a cutting-edge single-cell multiomics method designed for garnering detailed genetic insights into breast cancer.
pharmaphorum
NOVEMBER 16, 2022
Asked to elucidate the specifics of what the study had found, Dr Wykoff’s positivity over the “large, global clinical trial” was palpable; certainly, he is deeply passionate about his specialist area. “To To dive into specifics, […] OAKS and DERBY were identical trials. The specifics of an exciting prospect. Dr Charles C.
The Pharma Data
DECEMBER 11, 2020
And even when Black people with AML have the same access to treatment as white patients, their survival is shorter — something genetic differences might explain. But even when patients of both races received the same treatments, Black patients’ outcomes were worse, clinical trial data showed.
The Pharma Data
SEPTEMBER 3, 2020
Our findings could help to pick out those patients most likely to benefit from immunotherapy – and we’re keen to translate our work into clinical trials to test the benefit of different immunotherapeutic strategies to tackle this hard-to-treat form of pancreatic cancer.”. Source link.
Expert insights. Personalized for you.
105 
Let's personalize your content